Certificates

1. Wullenkord, R. et al. (2021) Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia. Ann Hematol. 100(2): 587-589
2. Demaret, J. et al. (2021) Monitoring CAR T-cells using flow cytometry. Cytometry B Clin Cytom. 100: 218-224
3. Mosti, L. et al. (2021) Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. Gene Ther. 28(9): 602-612
4. Ayuk, F. et al. (2020) Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A. Haematologica 105(6): 322-324
5. Badbaran, A. et al. (2020) Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR. Cancers (Basel) 12(7): 1970
6. Alzubi, J. et al. (2021) Automated generation of gene-edited CAR T cells at clinical scale. Mol Ther Methods Clin Dev. 20: 379-388
7. Cordes, N. et al. (2021) Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells. Mol Ther Methods Clin Dev. 21: 42-53
8. Lo Presti, V. et al. (2021)
   Efficient lentiviral transduction method to gene modify cord blood CD8

   ⁺

   T cells for cancer therapy applications.
   Mol Ther Methods Clin Dev. 21: 357-368